Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed July 2026
Key Takeaways
- The ATTR-CM treatment landscape is organized first by mechanism, then by continuity.
- Confirmation of ATTR-CM and subtype classification are prerequisites before initiating disease-directed therapy.
- Approved transthyretin stabilizers are indicated to reduce cardiovascular mortality and hospitalization, without a head-to-head ranking here.
- Disease-directed therapy complements—not replaces—supportive cardiac management, and persistence shapes how the landscape behaves.
Why Mechanism Is the First Organizing Principle
The ATTR-CM treatment landscape is best organized by mechanism of action rather than by brand-level comparison. Transthyretin-stabilizing therapy and upstream knockdown approaches both map to the same underlying biology, rather than by individual agent comparison. Approved transthyretin stabilizers are indicated for ATTR-CM to reduce cardiovascular mortality and cardiovascular-related hospitalization, which anchors the stabilizer category without ranking products against each other.
The two approved transthyretin stabilizers are summarized below according to their approved indications. This is not a comparative assessment.
| Stabilizer | Indicated population | Indicated to reduce |
|---|---|---|
| Tafamidis (VYNDAQEL / VYNDAMAX) | Adults with wild-type or hereditary ATTR-CM | Cardiovascular mortality and cardiovascular-related hospitalization |
| Acoramidis (ATTRUBY) | Adults with wild-type or hereditary ATTR-CM | Cardiovascular mortality and cardiovascular-related hospitalization |
Subtype Confirmation Is the Gatekeeper
Mechanism only becomes relevant after subtype confirmation establishes that the patient truly belongs on an ATTR-directed pathway. Confirming transthyretin amyloidosis and distinguishing hereditary from wild-type disease changes the treatment approach from a general consideration of options to a specific clinical decision because it determines whether disease-directed therapy is appropriate at all and informs family assessment. From there, the treatment selection should then be individualized according to disease subtype, clinical status, and approved therapeutic indications.
Disease-Directed Therapy Is Used Alongside Supportive Care
Disease-directed therapy complements supportive cardiac care and does not replace it. Diuretic-based congestion control as well as rhythm and conduction surveillance still remain central to ongoing symptom management, even when transthyretin-directed therapy is appropriate. Disease-directed and supportive therapies are not mutually exclusive; both are required components of comprehensive ATTR-CM management.
Continuity Is the Final Filter
Treatment continuity is an equally important consideration. In practice, the treatment decisions are influenced not only by mechanism and stage, but by whether treatment can be started early enough, tolerated, authorized, and maintained long enough to matter. Treatment persistence should therefore be considered an integral component of therapeutic planning and not a secondary concern. These factors influence treatment sequencing and, when stabilization is chosen, the choice between tafamidis and acoramidis within their approved labels.
Clinical Decision Point
A definitive treatment decision can only be made following amyloid subtype confirmation. Once ATTR-CM is confirmed, the practical questions are which mechanism fits the patient, whether disease-directed therapy can be sustained alongside supportive heart failure care, and how to keep treatment continuous. Mechanism of action and treatment continuity, rather than brand-level comparison, should guide the clinical treatment plan.
Frequently Asked Questions
How should the therapeutic approach to ATTR-CM be considered?
Consider mechanism first—transthyretin stabilization and upstream knockdown—and then by whether treatment can be sustained, rather than by brand-level comparison.
Why is subtype confirmation called the gatekeeper?
Disease-directed therapy is only appropriate once transthyretin amyloidosis is confirmed and hereditary versus wild-type disease is clarified; confirmation turns a list of options into a specific decision.
Does disease-directed therapy replace supportive cardiac care?
No. Diuretic-based congestion control, rhythm surveillance, and symptom management run alongside transthyretin-directed therapy and carry much of the day-to-day burden.
Why is long-term treatment continuity important?
Because a therapy only matters if it can be started early enough, tolerated, authorized, and maintained, treatment persistence is an important determinant of real-world therapeutic effectiveness.
Part of the Spotlight On ATTR-CM resource center.
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). PubMed
- VYNDAQEL and VYNDAMAX prescribing information. U.S. Food and Drug Administration
- ATTRUBY (acoramidis) prescribing information. U.S. Food and Drug Administration
- Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with ATTR-CM and/or receiving tafamidis prescriptions. PubMed
- Best Practices in Specialized Amyloidosis Centers in the United States. PubMed
- Current and Future Treatment Landscape of Transthyretin Amyloid Cardiomyopathy. Cardiology Therapy
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.